Compare SPRO & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPRO | ACOG |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.7M | 130.9M |
| IPO Year | 2017 | N/A |
| Metric | SPRO | ACOG |
|---|---|---|
| Price | $2.35 | $5.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 372.1K | 81.6K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,549,000.00 | $7,427,199.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $143.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $3.75 |
| 52 Week High | $3.22 | $11.54 |
| Indicator | SPRO | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 51.50 | 43.68 |
| Support Level | $2.26 | $5.66 |
| Resistance Level | $2.39 | $6.74 |
| Average True Range (ATR) | 0.09 | 0.38 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 70.83 | 16.51 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.